Recent guidelines on acute myocardial infarction (AMI) are based on randomized clinical trials (RCTs) and registries with selected patients, and may therefore not represent 'real-life'. This analysis shows for the first time nationwide trends in AMI from Germany.
Introduction
As a cause of death, cardiovascular disease ranks first in global mortality statistics during the past decades.
1,2 Current guidelines and recommendations for the management of acute myocardial infarction (AMI) 3 are based on data with limited comparability in terms of populations and data acquisition mode. Data on a large scale for Europe, or Germany in particular, are scarce, and yet populations differ markedly from the USA with respect to ethnic, geographic, or health economic characteristics. The often highly selected patients in randomized clinical trials (RCTs) lead to under-representation of certain population groups such as women, the elderly, or patients at high risk for complications or death. 4, 5 RCTs often include optimized diagnostic and therapeutic treatments which may not reflect real-life management. Accordingly, data from population-based surveys and registries revealed that conclusions drawn from RCTs have limited applicability to reality. 1, 6, 7 Moreover, contemporary population-based epidemiological and socio-economic data on AMI have been extrapolated from small-to medium-sized regional cohorts to ascertain an estimate for a large-scale population. The acquisition of recent hospital data on unselected populations of an entire nation allows defining more reliable trends on AMI reflecting 'real-life'.
In Germany, all hospitals are required by federal law to transfer data on all in-patient hospitalizations to the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, InEK; Siegburg, Germany; http://www.g-drg.de) since 2002. A large part of this data set was made available for scientific purposes by the Federal Statistical Office. Based on these nationwide data from the years 2005, 2007 , and 2009, we analysed all hospitalizations with AMI with regard to morbidity, in-hospital mortality, treatments, and associated costs.
Methods
The introduction of a diagnosis and procedure-related remuneration system (German Diagnosis Related Groups, G-DRG system) for all somatic in-patient services in Germany in 2003 has led to a precise and comprehensive acquisition of defined cases of illness. Detailed mandatory coding guidelines were implemented to ensure uniform documentation and billing. Thereby, all hospitals are required to transfer patient data on diagnoses, co-morbidities, medical services, or procedures and procedure-related complications to the Institute for the Hospital Remuneration System (InEK).
Data source
We obtained and analysed data from the Research Data Centers of the Federal Statistical Office and the Statistical Offices of the Laender (Statistisches Bundesamt, DESTATIS; https://www.destatis.de) for the years 2005, 2007 , and 2009 with respect to in-hospital outcomes and time trends related to AMI. The database comprises all in-patient treatments in German hospitals aggregated on a case base, except for treatments in psychiatric or psychosomatic units. We excluded medical care provided by office-based specialists with special admitting rights (1% of AMI inpatient treatments). Due to data privacy protection, all sub-groups less than six cases were excluded from the analysis. Access to the data was by remote execution directly on the anonymized original data. A statistical analysis program written in SAS (SAS 9.2: SAS Institute Inc., Cary, NC, USA) was executed by the Research Data Center.
Diagnoses and procedure codes
The German remuneration system requires the coding of a principal diagnosis for all in-hospital cases reflecting the underlying cause for hospital admission. Furthermore, an infinite number of additional diagnoses can be coded to document coexisting morbidities and complications. Each diagnosis must be coded according to the German Modification of the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10-GM). Annual adaptation is made by the German Institute for Medical Documentation and Information (Deutsches Institut fuer Medizinische Dokumentation und Information, DIMDI; Cologne, Germany; http://www.dimdi.de) but did not affect the established diagnoses during the analysed time period.
All hospitalized patients with an AMI (meaning within 28 days of onset of symptoms, diagnosis code: I21-I22) as their principal diagnosis were included in the analysis (see Supplementary material online, Figure S1 ).
Chronic kidney disease (CKD) was defined according to the classification of the National Kidney Foundation and encoded stage-related to glomerular filtration rate (N18.81 GFR ≥90 mL/min/ Left ventricular failure (LVF) was defined as 'Failure of adequate output by the left ventricle despite an increase in distending pressure and in end-diastolic volume, with dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.' Encoding was stage-related to the New York Heart Association classification (I50.11 NYHA I; I50.12 NYHA II, I50.13 NYHA III, I50.14 NYHA IV).
Similar to the ICD classification for diagnoses, all diagnostic, endovascular, and surgical procedures must be coded in detail according to the German Procedure Classification (OPS, see Supplementary material online, Figure S1 ).
Statistics
Frequencies are given as case number per 100 000 population based on the German population of the respective year. Proportions of hospitalizations are case numbers per 100 000 of total in-hospital cases. Mortality displays the percentage of in-hospital deaths within a designated subgroup. The analysis comprises all in-patient treated AMI cases in Germany and does not represent a sub-group or sample. The Chi-square test was performed to evaluate the significance of time trends (P-value , 0.01). For statistical analysis of trends in hospital length of stay, a linear regression model has been compiled. Statistical analysis was performed using SAS software (SAS 9.3: SAS Institute Inc., Cary, NC, USA) and the web-based statistics software VassarStats (http://vassarstats.net; R. Lowry). Figure  S2 ). The above-mentioned increase of NSTEMI cases resulted basically in an increase in the age group 65 -89 years, and to a smaller extent in the age group 45 -59 years. However, the ratio of NSTEMI in each individual age group remained relatively stable (Supplementary material online, Figure S3 ). In STEMI, a trend towards younger age groups could be observed. Percutaneous coronary interventions (PCI) were performed in 86.7, 89.9, and 91.1% of patients undergoing CA in STEMI, and 63.9, 66.5, and 66.5% in NSTEMI patients in 2005, 2007, and 2009, respectively. Although the proportion of CA decreased with increasing age .80 years., the ratio of PCI among those who received CA remained stable in STEMI (88.4% in ≥80 years) and further increased in higher age groups with NSTEMI ( Figure 2) . Stenting was applied to 93 211 patients, corresponding to 95% of PCIs performed in AMI patients in 2009 (96% STEMI, 95% NSTEMI). Among those, the majority of patients received bare-metal stents (65.6%) compared with 29.8% of implanted drug-eluting stents. Drug-eluting stents were used markedly more often in NSTEMI (55.8% of total stenting) than in STEMI (37.4% of total stenting).
Results

In
Thrombolytic therapy was applied to a minority of AMI patients 
Trends in in-hospital mortality
In-hospital mortality data for 2005 showed similar rates for STEMI (11.2%) and NSTEMI (11.0%, Table 3 ). Examining the course over the evaluated time, rates for STEMI increased (11.9% in 2007 and 12.2% in 2009). In contrast, NSTEMI mortality decreased to 9.9% in 2007 and remained stable at this level in 2009. In-hospital mortality was higher in STEMI compared with NSTEMI among all age groups (except for cases 35-39 years) and steeply rising with age in both STEMI and NSTEMI ( Figure 3 ). As stated above, cases with NSTEMI Figure 4) . Thereof, implantation of drug-eluting stents was associated with significantly lower mortality compared with bare-metal stents (mortality 3.8% DE stent, 6.3% BM stent in 2009). When thrombolytic agents were applied, in-hospital mortality was highly elevated in 2005 (mortality in STEMI 14.3, and 33.3% in NSTEMI). Rates further increased, and in 2009 almost every third STEMI (29%) and 40.1% of NSTEMI died upon thrombolysis. In-hospital mortality of patients treated with antiplatelet agents such as glycoprotein IIb/IIIa inhibitors was much lower compared with thrombolytic therapy: among treated patients, death occurred in 7.4% of STEMI and 5% of NSTEMI in 2009. Analyses of in-hospital mortality of CABG revealed a higher percentage in STEMI (11.6% in 2009) compared with NSTEMI (7.5%).
Costs and length of hospital stay
For 2005, no costing data were transferred and therefore could not be analysed. In 2007, the annual costs of the management of hospitalized AMI patients amounted to 1.18 billion E corresponding to 2.49% of total health expenses of all hospitalizations. The average cost per STEMI case was 5907 E (1.13% of total expenses) and 5333 E per NSTEMI case (1.36%, respectively, 
Discussion
Current guidelines for the management of AMI are predominantly based on RCTs that often include optimized diagnostic and therapeutic procedures which may not reflect real-life management. 1, 6, 7 But also major European studies such as the questionnaire-based ENACT 8 or the European Heart Survey on ACS (ACS-I and ACS-II 9 ) derived their data from selected medical centres with comparatively high rate of on-site catheterization facilities. The EUROAS-PIRE survey 10 or the MONICA/ KORA registry 11 excluded old patients (.70 years and . 74 years, respectively) and therefore lead-similar to the often highly selected populations of RCTs-to under-representation of population groups at high risk for complications or death. 4, 5 Other contemporary population-based Among all age groups, the ratio of CA (continuous lines) was higher in STEMI (black) compared with NSTEMI (grey) and decreased in all AMI cases aged .80 years. In-hospital mortality is displayed as total number of deaths and percentages related to the respective type of AMI and year. In-hospital mortality among sub-groups is annually displayed as absolute number of deaths and deaths per registered cases of the respective sub-group. P-values were calculated for trend over time for STEMI and NSTEMI (P , 0.01 was considered significant). DM, diabetes mellitus; LVF, left ventricular failure; CKD, chronic kidney disease; CA, coronary angiography; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
epidemiological and socio-economic data on AMI have been extrapolated from small-to medium-sized regional cohorts to ascertain an estimate for a large-scale population. This is the first time that comprehensive data from the unselected, complete hospital population of an industrialized nation have been analysed. These 'real-life' data are unique since they are based on obligatory electronic documentation of all patients hospitalized in Germany and, as part of the legally enforced DRG system being indispensable for reimbursement.
Frequency and hospitalization rate
In summary, with a frequency of 248 per 100 000 inhabitants and 1182 per 100 000 in-hospital treatments in 2009, the total AMI rate in Germany remained on a comparatively high level. 12, 13 In contrast, the frequency of STEMI decreased markedly (223%) in the German population from 2005 to 2009. This downward trend may be attributed to multiple factors, such as improvements in primary and secondary prevention 1,14 as well as in diagnostic and therapeutic procedures. In particular, there has been evidence for favourable changes in smoking behaviour 15 or cholesterol levels 16 in the recent past. On the contrary, an upward trend in the frequency of NSTEMI cases could be seen which is consistent with most reports from other industrial nations. 12, 17 Possible explanations for the increased frequency of NSTEMI include the use of high-sensitive troponin leading to elevated rates of diagnosed AMI. 18 -20 However, the use of high-sensitive troponin and change of AMI definition were already implemented in the European Society of Cardiology/American College of Cardiology guidelines since 2000, 21, 22 and therefore well before the evaluated years in our analysis (2005, 2007, and 2009 ). Additionally, NSTEMI patients had higher proportions of co-morbidities such as diabetes, hypertension, LVF, chronic kidney failure, and peripheral arterial disease in comparison with those with STEMI and therefore are at greater risk to suffer an acute cardiac event. 23, 24 Our data revealed consistently with others 25, 26 that NSTEMI patients were older than the averaged STEMI patient, suggesting that the progressive ageing of the population may additionally support the upward trend in NSTEMI frequency. Indeed, the absolute increase of NSTEMI with respect to age is mainly due to an increase of patients aged 65-89 years old, but relative data indicated that the risk of NSTEMI in each individual age group remained about stable over the evaluated period of time.
In how far and to which magnitude the in-patient coding was driven by the reimbursement policy, thereby leading to misclassification has to be evaluated in coding quality control studies. However, it should be noted that over the entire time period both, the DRGs and the reimbursement for patients with STEMI and NSTEMI were identical. Therefore, there was no financial incentive to change the coding of STEMI or NSTEMI. With regard to gender, almost two-thirds of all reported STEMI and about 60% of all NSTEMI occurred in men with a further reduction of the female proportion in both AMI types from 2005 to 2009. Therefore, an increasing number of AMI in women as has been reported previously 27 -29 could not be ascertained, but female gender was associated with higher in-hospital mortality.
Management and in-hospital mortality
Our data showed an increase of CA and PCI in both STEMI and NSTEMI. Coronary angiography and PCI ratios are comparable with values reported in other recent population-based studies. 30 -33 It could be shown that old patients receive less CA in STEMI and NSTEMI. However, those who got invasively diagnosed had the same chance for coronary intervention compared with younger age groups. In-hospital mortality was relatively stable at about 11% in AMI during 2005 to 2009. With a current mortality of 12.2% in STEMI and 9.9% in NSTEMI, rates are highly elevated compared with findings in recent RCTs (TRITON-TIMI 38 trial: STEMI 2.6% CF at 30 days; PLATO trial: NSTEMI 5% CF at 1 year). 34, 35 These differences may plausibly be explained by both, inherent selection processes and optimized treatments in RCTs. 1, 6, 7 Compared with the German data from the MONICA/ KORA registry from 2004 to 2010, the nationwide in-hospital mortality presented here was even higher than the 28-day case fatality (CF) of this regional registry (MONICA/KORA: STEMI 8.4%; NSTEMI 7.2%). 11 However, MONICA/KORA did not include patients older than 74 years who were consistently with others 25 shown firstly, to represent the majority of deceased patients (64.8% of all dead in 2009), and secondly, to have a noticeably higher CF than the average AMI patient. Furthermore, the separate consideration of the highly fatal left bundle branch block led to lower mortality rates in the STEMI group of the MONICA/KORA registry. Data on all cardiological units from the German ALKK registry showed a decreasing mortality in favour of early coronary revascularization. 36 Because of such differences in AMI definitions, sub-group characteristics, and context, there is limited comparability with recent cohort data from other European nations and the USA. Thus, the enrolment of younger patients with better risk profiles and a higher rate of invasive therapy accounted for the extremely low in-hospital mortality rate of 3.4% of AMI in the French registry FAST-MI. 37 This applies analogously for data presenting a 28-day CF of 4.7% on Q-wave AMI in Spain. 38 The inclusion of patients aged ≥75 years as performed in the Swedish SWEDEHEART registry, the British MINAP registry, the Italian BLITZ-Survey, and the Polish PL-ACS registry resulted in significantly higher in-hospital mortality rates ). These are within the range of American data based on the National Registry of Myocardial Infarction, 26 the National Hospital Discharge Service, 42 or the Olmsted County Area 43 showing a short-term mortality for AMI between 6.3 and 9.4%. Moreover, recent registries on large and rather unselected populations from the Netherlands, 44 Denmark, 45 and the UK 46 showed a similarly high in-hospital mortality as here it was shown for Germany. However, short-term mortality of AMI was reported to significantly decrease in industrialized nations during the past decades. 47 This trend is commonly attributed to better risk factor stratification as well as to improved medical treatment according to evidence-based medicine. 48, 49 Moreover, reduction of major complications and severity of AMI were shown to entail higher survival of AMI. 50 -52 Despite a reduced ratio of women and the elderly, who represent populations at high risk of death and despite the more frequent use of invasive therapy, STEMI mortality in Germany further increased against general trends. It can be assumed that the increased proportions of CKD and LVF were likely to redound to the rising mortality of STEMI patients. In-hospital mortality of NSTEMI patients slightly decreased despite even higher risk profiles and less aggressive therapeutic management. This presumably was owed to the detection of less severe cases by the use of high-sensitive biomarkers. 18 -20 Further, there is evidence that NSTEMI and STEMI frequencies are converging 13 with regard to the long-term mortality.
Strengths and limitations
The strengths of the presented data include its basis on the largesized unselected population of a whole nation. Taking account of the diverse characteristics of patients, the observed trends are of high applicability to daily practice. The findings of the analysis must be considered within the context of the limitations. First, the ICD classification did not allow to distinguish between first and subsequent event of myocardial infarction. Thus, a declining frequency of first AMI and an improved survival of events may mislead to the interpretation of stagnating hospitalizations. Second, in certain cases, hospital transfer was arranged in order to perform therapies with limited availability, such as catheterization or bypass surgery. Combined with the fact that the diagnosis of AMI included events within 28 days of onset of symptoms, this may have added to an underestimated ratio of interventional therapies (PCI, CABG). However, possible downward deviation of these ratios is unlikely to affect trends over time since methodology did not change. Importantly, data acquisition was case-but not patientbased and therefore implicated a certain number of double-counts of patients, e.g. by hospital transfer. Finally, this would lead to further underestimation of the presented mortality data.
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